Table 1 Drug–drug interaction alerts and override rates
DDI pair | DDI alerts (n) | Prescribers’ overrides (%) |
|---|---|---|
Factor Xa inhibitor + other anticoagulant | 16,859 | 92.4 |
QTc prolonging agent + antiarrhythmic agent (flecainide, sotalol) (QTc) | 6547 | 80.6 |
Antiarrhythmic agent (flecainide, amiodarone, sotalol) + antipsychotic (QTc) | 3151 | 88.5 |
Dabigatran + other anticoagulant | 2284 | 90.7 |
Antiarrhythmic agent (flecainide, amiodarone, sotalol) + tricyclic and related antidepressant (QTc) | 1931 | 90.9 |
Statin (simvastatin, atorvastatin) + non-azithromycin macrolides | 1287 | 86.6 |
Quetiapine + strong CYP3A4 inhibitor | 933 | 93.2 |
Statin (simvastatin, atorvastatin) + azole antifungal agent | 672 | 94.5 |
Statin (simvastatin, rosuvastatin) + cyclosporine | 655 | 82.6 |
Opioid + MAO inhibitor | 421 | 66.7 |
CYP3A4 substrate + CYP3A4 inducer | 342 | 92.4 |
Valproic acid + carbapenem | 280 | 88.9 |
Saccharomyces boulardii + glucocorticoid (high dose) | 254 | 75.2 |
Vitamin K antagonist + acetylsalicylic acid (analgetic dose) | 245 | 88.2 |
Droperidol, pimozide + macrolide (QTc) | 228 | 43.4 |
Intravenous calcium + ceftriaxone | 200 | 88.0 |
Antiarrhythmic agent (flecainide, amiodarone, sotalol, propafenone) + quinolone (QTc) | 176 | 82.4 |
Serotonergic antidepressant + linezolid | 163 | 91.4 |
Colchicine + CYP3A4 inhibitor (strong) | 158 | 91.1 |
Colchicine + macrolide | 154 | 92.9 |
Factor Xa inhibitor + azole antifungal agent | 150 | 91.3 |
Live vaccines + glucocorticoid | 112 | 70.5 |
Alcohol containing drugs + disulfiram | 110 | 61.8 |